Clinical Orthopaedics and Related Research®

, Volume 468, Issue 12, pp 3295–3303

Long-term Results for Minor Column Allografts in Revision Hip Arthroplasty

  • Paul T. H. Lee
  • Guy Raz
  • Oleg A. Safir
  • David J. Backstein
  • Allan E. Gross
Symposium: Papers Presented at the 2009 Closed Meeting of the International Hip Society

DOI: 10.1007/s11999-010-1591-2

Cite this article as:
Lee, P.T.H., Raz, G., Safir, O.A. et al. Clin Orthop Relat Res (2010) 468: 3295. doi:10.1007/s11999-010-1591-2

Abstract

Background

While acetabular structural allografts provide an important alternative for reconstructions, concerns remain with long-term graft resorption, collapse, and failure. Midterm studies of minor column (shelf) allograft suggest reasonable survival but long-term survival is unknown.

Questions/purposes

We therefore assessed long-term graft/cup survivorship, functional scores, radiographic resorption, and complications associated with minor column allograft.

Methods

We retrospectively reviewed 74 patients (85 hips) with a mean age of 54 years (range, 28–83 years) undergoing acetabular cup revision using a minor column allograft. A minor column allograft was used in uncontained acetabular bone defects sized between 30% and 50% of the acetabulum. Graft failure was considered to occur when the graft required revision with another graft, metal augment, reconstruction cage, or excision arthroplasty. The minimum followup was 5 years (mean, 16 years; range, 5.3–25 years).

Results

Twenty-three patients (27 hips) had rerevision for all causes at a mean time to rerevision of 6.9 years (range, 0.1–23). Fifteen grafts failed at a mean time-to-rerevision of 6.1 years (range, 0.5–23.2). The 15- and 20-year Kaplan-Meier survivorships were 61% and 55% for cups and 78% for grafts with rerevision for all causes as end point. With rerevision for aseptic loosening as end point, survivorships were 67% and 61% for cups and 81% for grafts. The mean modified Harris hip scores were 41 (range, 20–60) preoperatively, 73 (range, 40–95) at 1 year postoperatively and 73 (range, 26–93) at last followup.

Conclusion

The data may provide a long-term benchmark by which future treatments for Type III defects can be measured.

Level of Evidence

Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.

Copyright information

© The Association of Bone and Joint Surgeons® 2010

Authors and Affiliations

  • Paul T. H. Lee
    • 1
  • Guy Raz
    • 1
  • Oleg A. Safir
    • 1
  • David J. Backstein
    • 1
  • Allan E. Gross
    • 1
  1. 1.Division of Orthopaedic SurgeryMount Sinai HospitalTorontoCanada

Personalised recommendations